← Back to Writing What is ApoB and why your doctor doesn't test it
What is ApoB and why your doctor doesn’t test it
Your last blood panel probably included LDL cholesterol. Your doctor looked at the number, said “looks fine,” and moved on.
But LDL-C — the cholesterol measure on every standard lipid panel — is not the best predictor of whether plaque is building in your arteries. ApoB is. And there’s a good chance your doctor has never ordered it.
ApoB — apolipoprotein B — has more than 40 years of research behind it. The European Atherosclerosis Society and Canadian Cardiovascular Society recommend it as a primary target for cardiovascular risk assessment. US guidelines are still catching up.
What ApoB actually measures
Every lipoprotein particle capable of depositing cholesterol into your arterial walls carries one molecule of apolipoprotein B on its surface. LDL, VLDL, Lp(a). One ApoB molecule each.
ApoB counts those particles directly. LDL-C, by contrast, measures the cholesterol mass inside LDL particles — how much cholesterol is circulating, but nothing about how many particles are carrying it.
The particle count is what matters for plaque formation, because each particle can penetrate the arterial wall on its own. Two people can have the same LDL-C but wildly different ApoB levels. The person with more particles has more opportunities for plaque to form, even though their “cholesterol” looks identical on paper.
Think of it like traffic. LDL-C counts passengers. ApoB counts cars. More cars on the road means more collisions with the arterial wall, regardless of how full each one is.
Why ApoB is a better predictor than LDL-C
The Emerging Risk Factors Collaboration, a 2009 meta-analysis in The Lancet covering over 300,000 participants, found that ApoB-containing lipoproteins are the primary drivers of atherosclerotic cardiovascular disease. When LDL-C and ApoB disagree — which happens in roughly 20-30% of people — ApoB is the stronger predictor of cardiovascular events.
In one large registry study, roughly half of people hospitalized for a coronary event had LDL-C below 100 mg/dL. Their LDL looked fine. Their particle count did not.
The discordance shows up most in people with metabolic syndrome, insulin resistance, or elevated triglycerides. In those conditions, LDL particles tend to be smaller and denser — more particles, less cholesterol in each one. LDL-C stays in the normal range. ApoB climbs. Risk climbs with it. Nobody catches it because nobody ordered the right test.
Why most doctors don’t test it
Your doctor probably isn’t ignoring ApoB on purpose. The reasons are structural.
The basic lipid panel was designed decades ago: total cholesterol, LDL-C, HDL-C, triglycerides. That’s what the lab order template defaults to, and ApoB requires a separate order. Most electronic health records don’t prompt for it, so it doesn’t get ordered.
Then there’s the math. The average primary care physician manages 2,500 patients across panels that leave little room for anything outside the standard workflow. There’s rarely time to explain why ApoB matters, order the test, review the result, and adjust treatment. The system rewards throughput.
US guidelines haven’t helped. The AHA/ACC 2018 lipid guidelines mention ApoB but treat it as a secondary measure. The European Atherosclerosis Society and Canadian Cardiovascular Society are further ahead. Many US physicians trained before ApoB testing was widely discussed outside of lipidology.
There’s also plain institutional inertia. Ordering outside the standard panel triggers questions from the lab, from insurers, sometimes from the patient. Easier to stick with what everyone else orders.
None of these explain why skipping it is acceptable. They just explain why it keeps happening.
What the numbers mean
ApoB is measured in mg/dL, and the target depends on your risk level.
| Risk Level | ApoB Target |
|---|---|
| Low current risk | Below 100 mg/dL |
| Moderate risk | Below 80 mg/dL |
| High risk (established disease or multiple risk factors) | Below 65 mg/dL |
| Very high risk | Below 55 mg/dL |
The US population mean is approximately 95 mg/dL (NHANES). Many adults sit above even the most lenient threshold — carrying a cardiovascular risk factor that has never been identified or addressed.
Among Protocol members, median ApoB is 79 mg/dL, and 88% are below 100. That gap between the population mean of ~95 and our median of 79 is what happens when someone actually tests the number, explains what it means, and builds a plan to move it.
Your individual target depends on your full risk picture: family history, Lp(a), inflammatory markers, imaging results. A number without that context isn’t particularly useful. But you can’t make any of those decisions without the number.
What else should be tested alongside ApoB
ApoB doesn’t tell the whole story on its own.
Lp(a) is lipoprotein(a) — a genetic cardiovascular risk factor that doesn’t meaningfully change with lifestyle and is largely unaffected by most standard lipid therapies. Most physicians never order it. You test it once and it tells you your genetic baseline. If it’s elevated, it rewrites your entire risk calculation.
hsCRP is high-sensitivity C-reactive protein, a systemic inflammation marker. Elevated hsCRP alongside elevated ApoB compounds your risk well beyond what either suggests alone.
ApoE genotype determines how your body metabolizes lipids — whether statins work well for you, which dietary changes matter most. Also tested once.
Fasting insulin and HOMA-IR matter because insulin resistance directly affects how your body processes ApoB particles. This is why the ApoB/LDL-C discordance shows up so often in people with prediabetes: metabolic dysfunction pushes particle count up even when LDL-C looks normal. Protocol’s Metabolic Health protocol addresses this connection directly.
Protocol’s Cardiovascular Risk protocol tests all of these. It measures ApoB, stratifies your risk into four tiers, sets a target, and builds a plan to get you there. Three sessions. Six weeks.
What to do with your ApoB number
If you already have an ApoB result — from Function Health, a direct-to-consumer lab, or a forward-thinking doctor — here’s how to read it.
If you’re below your risk-appropriate target, retest annually. ApoB drifts upward with age, weight changes, and hormonal shifts. What’s optimal today may not be next year.
If you’re between 100 and 130 mg/dL, lifestyle changes can make a real difference — particularly dietary changes matched to your ApoE genotype, combined with exercise and weight management. But someone needs to design the protocol and verify it’s working with a follow-up test.
If you’re above 130, or have additional risk factors (elevated Lp(a), family history, high hsCRP), lifestyle alone is unlikely to close the gap. Pharmacotherapy — typically a statin, sometimes combined with ezetimibe — lowers ApoB by reducing hepatic cholesterol synthesis and increasing LDL receptor clearance. That’s not a failure of willpower. It’s biology.
A result sitting on a dashboard doesn’t lower your ApoB. The number needs interpretation, a plan, and a recheck to confirm the plan worked.
The gap between testing and action
Getting the test is the easy part. Function Health includes ApoB. So does InsideTracker. You can order it through Quest or Labcorp yourself.
What’s harder is what comes after. If your ApoB comes back at 115 and your primary care doctor doesn’t know what to do with it — or tells you it’s “not that high” — you’re left with a number and no plan.
That’s the actual gap. The test takes five minutes. Acting on it takes someone who knows what the number means alongside your other markers, can set a target, and will actually check whether it moved.
The blood test most physicals skip
ApoB is one of the strongest blood-based predictors of atherosclerotic cardiovascular risk — validated across hundreds of thousands of participants, a simple blood draw, available at any lab.
If you’ve never had one, you don’t have an accurate picture of your cardiovascular risk. LDL-C alone isn’t enough, particularly if you have markers of insulin resistance, a family history of heart disease, or elevated triglycerides.
Protocol’s Cardiovascular Risk protocol is built for this. It starts with a Foundation Assessment — the comprehensive baseline your annual physical was supposed to be — then moves into the focused 6-week cardiovascular protocol.